How To Properly Dose Retatrutide (And Why Microdosing Doesn't Work)

Watch the full video on Rumble: https://rumble.com/v7fo8ny-how-to-properly-dose-retatrutide-and-why-microdosing-doesnt-work.html

You've probably heard online that microdosing retitrutide daily is the best approach to minimize side effects. And in this video, I'm going to teach you exactly why that's wrong and show you how to dose this properly.

For context, I'm currently on six milligrams weekly. I'm down 25 pounds and I've helped hundreds of people get started with their own research on this drug, and the pattern I keep running into is the same one: someone splits their weekly dose into tiny daily shots, waits a month, and nothing happens.

To understand why nothing happens, you have to understand how the drug accumulates, because that's the whole story.

Your body works something like a bathtub, where the drug going in is water flowing from the tap and your body clearing the drug out is a drain at the bottom that never closes. Your kidneys and liver are always working, so the drain is always running, regardless of when you inject.

Retatrutide has a half life of six days. That's how long it takes for half of the drug to leave your system.

So if you inject two milligrams today, six days later you'll have about one milligram left and then six more days after that you'll have 0.5 left. The clearance keeps halving what's there, which means the amount leaving your body each day depends on how much is currently in it.

That last part is what most people miss. A nearly empty tub drains slowly because there's very little pressure behind the drain, and a full tub drains fast. So the more drug you accumulate, the faster your body eliminates it, until the two rates match.

The important concept here is something called steady state. That's when the bathtub stabilizes. That's when the amount going in finally equals the amount being eliminated.

Water is still pouring in and water is still going down the drain, but the level stops rising. For a drug with a six day half life, that takes roughly four to five half lives, which lands you at about a month. From what I have seen with clients, that timeline holds up, though I cannot point you to a study that measured the exact week retatrutide plateaus in humans at each dose.

If you inject two milligrams weekly, you're dumping a bucket in once and letting it sit for seven days. After about four weeks, you'll have a consistent amount in your system, about 3.6 milligrams on average, and that figure comes from my own reading of how the drug accumulates rather than from a published steady state table, so treat it as an estimate. Between injections your level rises and falls, but it oscillates around a high number.

Take the daily version and the math falls apart fast. If you take 0.1 milligram every single day, that's 0.7 milligrams total per week, which sounds like you're nearly matching the two milligram weekly protocol if you squint at the totals.

The comparison doesn't hold up once you factor in the drain. Because it's always running and your tub level never gets high, you're adding a teaspoon to a container that's barely holding anything. So after four weeks at 0.1 milligram daily, you only have about 0.9 in your system on average. Compare that to the 3.6 milligram from weekly dosing. I have never seen a published pharmacokinetic study comparing these two schedules head to head, so that 0.9 figure is arithmetic from the half life, not a measured trial result.

Daily microdosing gives you only 25% of what you get from proper weekly dosing.

Injecting more often just feels like the more serious approach, but frequency doesn't actually work that way. Frequency doesn't determine how much drug is working in your body, total input against the clearance rate does, and microdosing lowers total input while the clearance rate stays exactly where it was.

The phase 2 trial is where this stops being theory. They studied 338 adults with obesity for 48 weeks, and the trial escalated participants through several dose arms while a placebo group ate and lived the same way. (Jastreboff 2023)

The lowest dose that they tested was 0.5 milligrams once per week. People on that dose lost 3.19% of their body weight, and the placebo group lost 3%, so the drug beat doing nothing by 0.19 percentage points. That comparison is the closest thing the literature gives us to a test of very low dosing, and the research hasn't gone lower than that.

Move up the dosing ladder and the numbers tell a completely different story. One milligram weekly produced 8.7% weight loss, four milligrams produced 17.1%, eight milligrams produced 22.8%, and twelve milligrams produced 24.2%. (Jastreboff 2023)

Two milligrams weekly is a starting dose. It doesn't even appear in the headline results because the trial used it as a ramp, so when you microdose, you're using 25% of a starting dose that's already too low.

There's a second argument for microdosing, and it's the one that sounds most reasonable: smaller doses, fewer side effects. There's some truth buried in that claim, since nausea genuinely rises alongside how concentrated the dose is.

The problem is what else scales with it. Retatrutide activates three receptors at once, the GLP-1, GIP, and glucagon receptors, and the GLP-1 arm is what drives both the appetite suppression and the nausea. (Tetelbaun 2024)

Those signals travel through the same receptor population in the same brain regions, so you can't turn down one dial without turning down the other. Dose low enough to feel nothing and you'll also lose nothing.

The escalation used in the trial is the one I'd copy. Weeks 1 through 4 at 2 milligrams weekly. Then 5 through 8, they increased to 4 milligrams. Then 9 through 12, they went up to 6 or 8 milligrams weekly, and from week 13 onward some participants went as high as 12 if they were tolerating it.

There's a reason the trial spaced increases four weeks apart rather than moving faster. It's how long the new dose needs to fully accumulate, so if you jump at week two you're judging a dose you haven't actually reached yet, and you won't know whether your results or your nausea came from the new number or from the old one still filling in.

And the reason we start at 2 milligrams is because studies show that starting there reduced early side effects compared to starting at 4, which is why the trial used it as a ramp rather than a treatment dose.

Then there's what the scale does, which throws more people off than the dosing math.

You're probably going to see a big drop on the scale of 5, 10, or even 15 pounds in the first few weeks, and none of that is fat. Your body holds roughly 400 to 500 grams of glycogen in the liver and muscles, and every gram of glycogen carries about three grams of water with it.

So when you start eating less because your appetite is suppressed, your body burns through that glycogen that's stored much faster, and you're not eating enough carbohydrate to put it back. And that's where that first 5 to 10 pounds comes from.

Real weight, real number on the scale, mostly water.

And here's why that matters. Because between weeks 3 and 6, there's going to be a lot of people out there who say, oh, I'm hitting a plateau, when what actually happened is their glycogen hit a new lower floor and stopped dropping.

Eventually that water weight stops draining out. Fat loss continues underneath it at a pace that a bathroom scale barely registers week to week, especially since you're still at 2 or 4 milligrams during that window.

That's the moment people increase the dose, and it's the wrong move, because the fix is checking whether you're tracking food, hitting protein, and actually sitting in a calorie deficit. Appetite gets suppressed by the drug itself, but nothing about that automatically creates the deficit you still need to build.

Timing wise, appetite suppression usually shows up from the first injection, steady state arrives around week four, but week 12 is when the results start compounding, because that's when escalation finishes and you're finally at a maintenance dose.

In the trial, the higher dose groups were down roughly 10% at week 12. But then by week 48, that's when they've lost that 24% of their body weight that you see in all the reports from the clinical trials. (Jastreboff 2023)

More than half the total loss happened after week 12.

There is a lot more of this inside the free community, and it is genuinely free, so if you want somewhere to ask the follow-up question the men's group is here: https://www.skool.com/jh-iron-forge-brotherhood/about

Research: Jastreboff AM, Kaplan LM, Frías JP et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity, N Engl J Med 2023. Tetelbaun L, Mullally JA, Frishman WH, The First Triple Agonist for Antiobesity: Retatrutide, Cardiol Rev 2024.

References:

Tetelbaun L, Mullally JA, Frishman WH. The First Triple Agonist for Antiobesity: Retatrutide. Cardiol Rev. 2024. https://pubmed.ncbi.nlm.nih.gov/39724554/

Jastreboff AM, Kaplan LM, Frías JP et al.. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/